Emergent BioSolutions Inc. (EBS) |
|
103.64 2.01 (1.98%)
|
09-29 01:07 |
|
Open: |
102.28 |
Pre. Close: |
101.63 |
|
High:
|
103.8 |
Low:
|
101.18 |
|
Volume:
|
355,909 |
Market Cap:
|
5,485M |
|
|
|
|
Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. The company is headquartered in Gaithersburg, Maryland and currently employs 1,705 full-time employees. The firm focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. The company focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs). The PHTs operates through two categories: Chemical, Biological, Radiological and Nuclear, as well as explosive-related threats and emerging infectious diseases. The company operates through four business units: Vaccines and Anti-infectives; Antibody Therapeutics; Devices, and Contract Manufacturing. Vaccines and Anti-infectives business unit consists of BioThrax, which is for the general use prophylaxis and post-exposure prophylaxis of anthrax disease. Devices business unit consists of marketed products, such as Reactive Skin Decontamination Lotion Kit (RSDL) and Trobigard (atropine sulfate, obidoxime chloride). |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
103.928 - 104.313 |
104.313 - 104.623 |
|
Low:
|
100.141 - 100.625 |
100.625 - 101.015 |
|
Close:
|
102.904 - 103.661 |
103.661 - 104.269 |
|
Technical analysis |
as of: 2020-09-28 4:31:55 PM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 138.56 One year: 153.97 |
| Support: |
Support1: 97.30 Support2: 80.95 |
| Resistance: |
Resistance1: 118.63 Resistance2: 131.82 |
| Pivot: |
101.61  |
| Moving Average: |
MA(5): 101.47  MA(20): 103.61
MA(100): 96.91 MA(250): 73.51 |
| MACD: |
MACD(12,26): -3.39 Signal(9): -3.53 |
| Stochastic oscillator: |
%K(14,3): 38.35 %D(3): 30.01 |
| RSI: |
RSI(14): 45.57 |
| 52-week: |
High: 137.61 Low: 46.37 Change(%): 97.9 |
| Average Vol(K): |
3-Month: 91366 10-Days: 52115 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed above its Short term moving average. Short term moving average is currently below mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.EBS has closed below upper band by 23.6%. Bollinger Bands are 70.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to EBS's normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Headline News |
Fri, 25 Sep 2020
Emergent BioSolutions Inc. (EBS) Is Posting Gains, Do You Know Why? - investmillion.com
Fri, 25 Sep 2020
Fuad El-Hibri Sells 25,535 Shares of Emergent Biosolutions Inc (NYSE:EBS) Stock - MarketBeat
Mon, 21 Sep 2020
Emergent BioSolutions Sees Hammer Chart Pattern: Time to Buy? - Yahoo Finance
Fri, 18 Sep 2020
Has Emergent Biosolutions (EBS) Outpaced Other Medical Stocks This Year? - Nasdaq
Wed, 16 Sep 2020
ValuEngine Downgrades Emergent Biosolutions (NYSE:EBS) to Sell - MarketBeat
Fri, 11 Sep 2020
Emergent Biosolutions (EBS) Stock Sinks As Market Gains: What You Should Know - Yahoo Finance
|
Financial Analysis |
| Growth |
|
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
|
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
 |
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
 |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Neutral |
Price to Earnings: |
Outperform |
| Return on Equity: |
Neutral |
Debt to Equity: |
Outperform |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NYSE |
| Sector: Healthcare |
| Industry: Drug Manufacturers General Specialty & Generic |
| Shares Out. (M) |
53 |
| Shares Float (M) |
47 |
|
% Held by Insiders
|
15.60 |
|
% Held by Institutions
|
88.96 |
|
Shares Short (K)
|
2,470 |
|
Shares Short P. Month (K)
|
2,570 |
Stock Financials |
|
EPS
|
3.190 |
|
EPS Est This Year
|
1.540 |
|
EPS Est Next Year
|
2.260 |
|
Book Value (p.s.)
|
22.660 |
|
Profit Margin
|
13.52 |
|
Operating Margin
|
23.80 |
|
Return on Assets (ttm)
|
7.8 |
|
Return on Equity (ttm)
|
15.6 |
|
Qtrly Rev. Growth
|
62.3 |
|
Gross Profit (p.s.)
|
9.129 |
|
Sales Per Share
|
23.810 |
|
EBITDA (p.s.)
|
7.721 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
305 |
|
Levered Free Cash Flow (M)
|
157 |
Stock Valuations |
|
PE Ratio
|
32.49 |
|
PEG Ratio
|
|
|
Price to Book value
|
4.57 |
|
Price to Sales
|
4.35 |
|
Price to Cash Flow
|
18.00 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
